Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABP NASDAQ:AYTU NASDAQ:FNCH NASDAQ:SXTP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABPAbpro$0.25+0.5%$0.24$0.15▼$13.00$20.31M0.037.37 million shs281,537 shsAYTUAytu BioPharma$2.35+0.2%$2.34$0.95▼$2.85$21.09M0.22574,519 shs20,366 shsFNCHFinch Therapeutics Group$12.03-7.5%$12.68$10.15▼$15.85$19.32M1.192,166 shs1,000 shsSXTP60 Degrees Pharmaceuticals$1.46+2.8%$1.65$1.22▼$12.45$5.95M2.73984,231 shs49,310 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABPAbpro+2.86%+4.00%+5.88%+19.37%+25,209,900.00%AYTUAytu BioPharma0.00%+3.07%-2.08%+47.80%-6.00%FNCHFinch Therapeutics Group0.00%+2.34%+4.25%-4.05%+1.48%SXTP60 Degrees Pharmaceuticals+0.71%+11.81%+6.77%-50.35%-78.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABPAbproN/AN/AN/AN/AN/AN/AN/AN/AAYTUAytu BioPharma4.0713 of 5 stars3.54.00.03.43.00.00.6FNCHFinch Therapeutics Group0.5471 of 5 stars0.03.00.00.00.81.70.6SXTP60 Degrees Pharmaceuticals3.032 of 5 stars3.35.00.00.02.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABPAbpro 3.00Buy$4.001,479.16% UpsideAYTUAytu BioPharma 3.00Buy$10.00324.81% UpsideFNCHFinch Therapeutics Group 0.00N/AN/AN/ASXTP60 Degrees Pharmaceuticals 2.50Moderate Buy$3.00105.48% UpsideCurrent Analyst Ratings BreakdownLatest SXTP, AYTU, FNCH, and ABP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025SXTP60 Degrees PharmaceuticalsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $3.008/30/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)8/14/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)7/29/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)7/12/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)7/1/2025AYTUAytu BioPharmaLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.006/30/2025AYTUAytu BioPharmaAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/27/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)6/11/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABPAbpro$183K110.96N/AN/A($0.21) per share-1.21AYTUAytu BioPharma$81M0.26N/AN/A$4.64 per share0.51FNCHFinch Therapeutics GroupN/AN/AN/AN/A$14.25 per shareN/ASXTP60 Degrees Pharmaceuticals$300K19.95N/AN/A($1.76) per share-0.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABPAbpro-$7.23MN/A0.00∞N/AN/AN/A-241.16%N/AAYTUAytu BioPharma-$15.84M-$0.72N/A∞N/A2.37%3.51%0.91%9/25/2025 (Estimated)FNCHFinch Therapeutics Group-$74.75M-$8.82N/A∞N/AN/A-69.14%-26.92%N/ASXTP60 Degrees Pharmaceuticals-$7.95M-$50.41N/AN/AN/A-976.86%N/A-133.88%11/13/2025 (Estimated)Latest SXTP, AYTU, FNCH, and ABP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/25/2025Q4 2025AYTUAytu BioPharma-$0.02N/AN/AN/AN/AN/A8/13/2025Q2 2025ABPAbproN/A-$0.04N/A-$0.05N/AN/A8/13/2025Q2 2025SXTP60 Degrees Pharmaceuticals-$1.24-$1.25-$0.01-$1.25$0.32 million$0.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABPAbproN/AN/AN/AN/AN/AAYTUAytu BioPharmaN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/ASXTP60 Degrees PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABPAbproN/A0.150.15AYTUAytu BioPharma0.271.030.87FNCHFinch Therapeutics GroupN/A3.873.87SXTP60 Degrees PharmaceuticalsN/A2.271.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABPAbpro23.30%AYTUAytu BioPharma33.49%FNCHFinch Therapeutics Group21.77%SXTP60 Degrees Pharmaceuticals7.96%Insider OwnershipCompanyInsider OwnershipABPAbpro20.80%AYTUAytu BioPharma3.60%FNCHFinch Therapeutics Group44.90%SXTP60 Degrees Pharmaceuticals1.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABPAbpro1580.17 million63.49 millionN/AAYTUAytu BioPharma1608.98 million8.65 millionNot OptionableFNCHFinch Therapeutics Group1901.61 million885,000No DataSXTP60 Degrees Pharmaceuticals34.10 million4.04 millionNot OptionableSXTP, AYTU, FNCH, and ABP HeadlinesRecent News About These Companies60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference4 hours ago | globenewswire.com60 Degrees Pharmaceuticals (NASDAQ:SXTP) Given Sell (E+) Rating at Weiss RatingsAugust 31 at 2:13 AM | americanbankingnews.com60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment ConferenceAugust 21, 2025 | globenewswire.com60 Degrees selects Icahn School of Medicine as central site for Phase II studyAugust 19, 2025 | msn.com60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic BabesiosisAugust 19, 2025 | globenewswire.com60 Degrees Pharmaceuticals Announces Second Quarter 2025 ResultsAugust 13, 2025 | globenewswire.com60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public OfferingJuly 16, 2025 | globenewswire.com60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025July 15, 2025 | finanznachrichten.de60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration ...July 15, 2025 | finanznachrichten.de60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public OfferingJuly 15, 2025 | globenewswire.com60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 BillionJuly 15, 2025 | globenewswire.comSXTP - 60 Degrees Pharmaceuticals Inc Valuation - MorningstarJuly 3, 2025 | morningstar.comM60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Director Cheryl Xu Acquires 5,000 SharesJune 6, 2025 | insidertrades.com60 Degrees Pharmaceuticals Reports Significant Discrepancy in Babesiosis Case Estimates and Plans for New Drug Application in 2026June 5, 2025 | nasdaq.com60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle FormatJune 4, 2025 | globenewswire.comBabesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees PharmaceuticalsJune 3, 2025 | globenewswire.com60 Degrees Pharmaceuticals Announces First Quarter 2025 ResultsMay 15, 2025 | globenewswire.comBabesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma SurveyApril 22, 2025 | globenewswire.comWhy 60 Degrees Pharmaceuticals, Inc. (SXTP) Went Down On Thursday?April 10, 2025 | insidermonkey.comGeoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21April 10, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSXTP, AYTU, FNCH, and ABP Company DescriptionsAbpro NASDAQ:ABP$0.25 +0.00 (+0.48%) As of 11:15 AM EasternAbpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.Aytu BioPharma NASDAQ:AYTU$2.35 +0.00 (+0.17%) As of 11:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.Finch Therapeutics Group NASDAQ:FNCH$12.03 -0.97 (-7.46%) As of 10:47 AM EasternFinch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.60 Degrees Pharmaceuticals NASDAQ:SXTP$1.46 +0.04 (+2.82%) As of 11:34 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Kohl’s Stock Rebound Faces a Showdown With Short Sellers Tesla Bulls Need to Tread Very Carefully Right Now Amazon Faces Rare Downgrade—Is the Rally at Risk? What to Watch for From D-Wave Now That Earnings Are Done Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
